Disc stack centrifuges play a critical role in antibody purification processes. Separating cells from culture broth via centrifugal force, they effectively remove cell debris and deliver high-quality feedstock for downstream purification. Featuring fully enclosed operation and gentle separation conditions, these units preserve antibody activity and minimise protein denaturation. Industrial application feedback demonstrates that implementation of disc stack centrifuges boosts antibody recovery by 10%–20%, achieves purity above 98%, and cuts production costs by 20%–30%. Leading disc stack centrifuge manufacturers including Alfa Laval and Siemens continuously launch upgraded products with enhanced separation efficiency, intelligent control systems, improved energy efficiency and environmental performance. Despite challenges such as high shear force risks and complex equipment cleaning and maintenance, these issues can be mitigated via design optimisation and process parameter tuning. Application cases from domestic monoclonal antibody manufacturers validate the substantial value of disc stack centrifuges, indicating broad application prospects that will support the biopharmaceutical industry in delivering high-efficiency, low-cost antibody production.
1 Overview of Antibody Purification Processes
1.1 Objectives and Requirements of Antibody Purification
The primary objective of antibody purification is to isolate high-purity, high-activity antibody therapeutics from complex bioreactor harvest fluid, while eliminating process-related and product-related impurities. Process-related impurities encompass whole cells, cell debris, host cell proteins (HCPs), host cell DNA (HCD) and media components. Product-related impurities mainly include antibody fragments and aggregates. In addition, purification workflows must deliver sufficient viral clearance and inactivation capacity to guarantee drug safety. Per U.S. FDA requirements, antibody purity must exceed 95%, and HCP residual levels shall be controlled below 1 ppm to secure therapeutic efficacy and safety.
1.2 Introduction to Purification Workflow
A typical antibody purification workflow consists of the following core stages:
1.2.1 Primary Clarification
Primary clarification aims to remove whole cells and large cell debris. Common technologies include centrifugation and depth filtration. Centrifugation enables robust removal of most cells and cell debris yet is limited in throughput; depth filtration is suitable for large-scale processing, removing particulate contaminants via physical retention and adsorption, while partially eliminating HCPs and HCD simultaneously.
1.2.2 Affinity Capture
Affinity chromatography serves as the cornerstone of antibody purification for target capture. Protein A affinity chromatography represents the most widely adopted approach, leveraging specific binding between Protein A and the Fc region of antibodies to isolate antibodies from complex feedstock with high efficiency. Antibody purity exceeding 90% can be achieved after this step. Featuring simple operation and high antibody recovery, it is the preferred technology in antibody purification workflows.
1.2.3 Intermediate Purification
Intermediate purification further removes impurities to elevate antibody purity. Main techniques include ion exchange chromatography (IEX) and hydrophobic interaction chromatography (HIC). IEX separates targets and impurities based on charge differences: cation exchange chromatography removes positively charged impurities, whereas anion exchange chromatography eliminates negatively charged contaminants. HIC utilises discrepancies in hydrophobicity between antibodies and impurities under high-salt conditions to remove contaminants difficult to separate via IEX.
1.2.4 Polishing
Polishing constitutes the final purification stage to strip residual impurities and bring antibodies to compendial purity standards. Typical polishing technologies include hydroxyapatite chromatography and size-exclusion chromatography (SEC). Hydroxyapatite chromatography further removes antibody aggregates and fragments to improve antibody homogeneity; SEC primarily eliminates small-molecule impurities and performs buffer exchange to adjust antibodies to the target buffer system and concentration.
1.2.5 Viral Clearance and Inactivation
Given potential viral contamination risks during antibody manufacturing, viral clearance and inactivation are indispensable purification unit operations. Main technologies include low-pH incubation and viral filtration. Low-pH incubation achieves viral inactivation, while viral filtration physically retains viral particles. Combined deployment effectively mitigates viral contamination risks and ensures drug safety. The full antibody purification workflow is sophisticated and intricate, requiring optimisation and adjustment according to antibody characteristics and production specifications to realise efficient, cost-effective antibody purification.
2 Fundamental Principles of Disc Stack Centrifuges
2.1 Generation Mechanism of Centrifugal Force Field
The working principle of disc stack centrifuges follows Newtonian mechanics. When the rotor rotates at high speed, materials inside the unit are subjected to centripetal force that drives particles toward the rotor wall. In accordance with Newton’s Second Law, \(F=ma\), where F denotes force, m mass, and a acceleration. Within centrifuges, centripetal acceleration a is determined by angular velocity \(\omega\) and radius r, expressed as \(a=\omega^2r\). Hence, centrifugal force \(F_c=m\omega^2r\). This formula indicates that particles with greater mass, higher rotational speed and larger radial position experience stronger centrifugal force. Denser particles settle toward the rotor wall under centrifugal force, while lighter liquid phases migrate toward the centre, enabling solid-liquid or liquid-liquid separation.
2.2 Factors Affecting Separation Performance
Separation efficiency of disc stack centrifuges is governed by multiple factors:
2.2.1 Material Properties
1.Density difference: The density differential between different fractions constitutes the decisive factor for separation. Greater density disparity yields superior separation performance. For cell-culture broth separation, cells possess higher density than culture media and settle rapidly onto the rotor wall under centrifugal force.
2.Particle size: Particle dimension impacts settling behaviour. Larger particles settle readily under centrifugal force, whereas fine particles demand higher centrifugal force or extended residence time for effective separation. Generally speaking, suspensions containing particles larger than 1 μm can be efficiently processed by disc stack centrifuges.
2.2.2 Operational Parameters
1.Rotational speed: Rotational speed directly governs centrifugal force magnitude. Higher speed generates stronger centrifugal force and improves separation efficiency, yet excessive speed accelerates equipment wear and increases energy consumption. Disc stack centrifuges typically operate at 3,000–10,000 revolutions per minute (rpm); the optimal speed is selected based on material properties and separation requirements.
2.Feed flow rate: Feed flow determines material residence time inside the centrifuge and separation outcomes. Lower flow extends residence time and enhances separation performance yet reduces throughput. Higher flow boosts processing capacity but may compromise separation efficacy. Feed flow must be optimised according to equipment model and material characteristics to balance separation efficiency and throughput.
3.Disc spacing: Disc spacing affects flow paths and separation performance between discs. Reduced disc spacing expands available separation area and improves separation efficiency yet increases flow resistance and limits throughput. Larger disc spacing lowers flow resistance and raises throughput but may degrade separation performance. Disc spacing normally ranges from 0.5 mm to 2 mm, selected by comprehensive evaluation of material properties and separation targets.
2.2.3 Equipment Design and Maintenance
1.Disc configuration: Disc geometry and surface properties exert significant influence on separation performance. Optimised disc design improves fluid flow and separation efficiency. For instance, discs with special surface coatings reduce material adsorption, enhance separation performance and facilitate equipment cleaning.
2.Equipment maintenance: Routine maintenance ensures stable operation and consistent separation performance, including inspection and replacement of worn components, calibration of speed sensors, and cleaning of disc stacks and rotors. Proper maintenance extends service life, lowers failure rates and stabilises separation results.
3 Specific Applications of Disc Stack Centrifuges in Antibody Purification
3.1 Clarification of Cell Culture Broth
Disc stack centrifuges undertake a vital role in the clarification stage of antibody purification. Cell culture broth contains abundant whole cells, cell debris and target antibodies; effective clarification lays a foundation for subsequent purification steps.
1.Efficient removal of cells and debris: Disc stack centrifuges generate centrifugal force thousands of times gravitational acceleration, driving cells and large cell debris to settle onto the rotor wall and separate from culture supernatant. For example, Alfa Laval CF-series high-speed disc stack centrifuges adopt patented bottom-feed design to achieve gentle acceleration with low shear, maximising cell integrity while operating at high separation factors to remove minor debris generated by cellular autolysis. When processing mammalian cell culture broth, these centrifuges eliminate over 90% of whole cells and cell debris, delivering clarified supernatant for downstream purification.
2.Minimised protein denaturation and activity loss: Fully enclosed construction eliminates bubble formation and isolates process fluids from ambient air, restricting temperature rise during centrifugation and preserving protein activity. This feature is critical for antibody manufacturing, as antibodies are sensitive proteins prone to denaturation under adverse conditions. For production of shear-sensitive antibodies, disc stack centrifuges confine antibody activity loss within 5%, far outperforming conventional separation technologies.
3.Reduced downstream purification costs: Efficient clarification by disc stack centrifuges drastically lowers the consumption of depth filter capsules. Case data from a domestic monoclonal antibody manufacturer shows that introduction of Alfa Laval high-speed disc stack centrifuges cuts depth filter capsule usage by 60%, delivering substantial cost savings. Thorough removal of cells and debris alleviates loading on depth filters, extends filter service life, and avoids production delays and material losses caused by filter clogging.
3.2 Process Interfacing with Downstream Purification Steps
Beyond broth clarification, disc stack centrifuges enable seamless integration with subsequent unit operations to build high-efficiency purification workflows.
1.Interfacing with affinity chromatography: Supernatant treated by disc stack centrifuges can be fed directly into affinity chromatography. Extensive removal of cells and debris reduces impurity interference, enabling Protein A affinity chromatography to capture antibodies more efficiently. Experimental data reveals that supernatant pre-clarified via disc stack centrifuges improves antibody recovery in Protein A affinity chromatography by 10%–15%, shortens column equilibration and cleaning cycles, and elevates overall productivity.
2.Interfacing with ion exchange chromatography: Low impurity levels in pre-clarified supernatant enhance selectivity and efficiency of IEX. For cation exchange chromatography, supernatant depleted of cell debris facilitates removal of positively charged impurities and improves antibody purity. Moreover, gentle separation conditions preserve antibody charge profiles, enabling effective binding between antibodies and ion exchange media for efficient separation.
3.Interfacing with viral clearance and inactivation: Low levels of particulate contaminants in pre-clarified supernatant benefit viral filtration. Viral filtration relies on physical retention of viral particles; excessive cell debris and particulates easily foul filter membranes and reduce filtration throughput. Pre-treatment with disc stack centrifuges increases viral filtration flux by 20%–30% while maintaining viral removal efficiency above 99.9%, safeguarding antibody safety.
4 Advantages and Challenges of Disc Stack Centrifuges
4.1 Advantage Analysis
Disc stack centrifuges deliver prominent merits for antibody purification, boosting separation efficiency, securing product quality and optimising production costs.
1Powerful separation capacity: Strong centrifugal force enables effective separation of whole cells, cell debris and culture broth. Over 90% of cells and cell debris can be removed to supply clarified supernatant for downstream processing. As exemplified by Alfa Laval CF-series high-speed disc stack centrifuges, patented bottom-feed design preserves cell integrity while operating at high separation factors to remove minor autolytic debris.
2.Preservation of protein activity: Fully enclosed design prevents aeration and bubble generation, limits temperature elevation and retains protein activity. For antibody manufacturing, activity loss can be controlled within 5% when disc stack centrifuges are deployed for clarification.
3.Cost reduction: Effective clarification reduces consumption of downstream depth filter capsules. As demonstrated by domestic monoclonal antibody manufacturers, filter capsule usage can be cut by 60% after adopting disc stack centrifuges, lowering filtration expenditure, extending filter service life and avoiding production interruptions and material waste.
4.Excellent compatibility with downstream workflows: Clarified supernatant can directly enter affinity chromatography to improve antibody recovery and production efficiency. For IEX, reduced particulate impurities enhance removal of charged contaminants and raise antibody purity. During viral clearance, low particulate loading improves viral filtration flux and viral removal efficiency.
4.2 Existing Challenges and Mitigation Strategies
Despite multiple strengths, disc stack centrifuges face challenges related to operation, maintenance and process optimisation.
Equipment Operation and Maintenance
1.Risk of high shear force: Exposure to excessive shear force may rupture shear-sensitive cells, releasing nucleic acids and host proteins and compromising downstream purification. This risk can be addressed via low-shear centrifuge designs such as Alfa Laval CF-series with patented bottom-feed architecture, delivering gentle acceleration to protect cell integrity.
2.Complex cleaning and maintenance: Strict standard operating procedures are required for cleaning and maintenance to sustain separation performance and service life. Routine maintenance includes inspection and replacement of worn components, sensor calibration, and cleaning of disc stacks and rotors. Integration of Clean-in-Place (CIP) and Steam-in-Place (SIP) systems achieves 360° deadleg-free cleaning, reduces manual labour and shortens cleaning cycles.
Process Optimisation
1.Trade-off between throughput and separation performance: Large-scale production requires balanced throughput and separation quality. Higher feed flow raises processing capacity yet may degrade separation efficiency. Process optimisation can be implemented via laboratory trials to determine optimal feed flow and rotational speed, alongside tuning disc spacing based on material properties to achieve balanced separation performance and throughput.
2.Synergistic optimisation with complementary separation technologies: Although disc stack centrifuges excel at primary clarification, antibody purification relies on coordinated deployment of multiple separation technologies. Systematic optimisation of the full workflow is required to align disc stack centrifuges with affinity chromatography, IEX, viral clearance and other unit operations to construct integrated high-efficiency purification processes. For instance, tuning clarification performance of disc stack centrifuges improves feed quality entering affinity chromatography and lifts antibody recovery and purity.
5 Disc Stack Centrifuge Products and Technical Development
5.1 Main Brands and Product Characteristics
Multiple reputable manufacturers operate in the disc stack centrifuge market with differentiated technical solutions:
Sino Bioengineering
1.Automatic feed control: Fully enclosed automatic feed architecture with high-precision regulating valves and real-time flow monitoring ensures stable material transport, protects active species such as cells and proteins, improves product yield, and suits separation and purification of sensitive materials including biologic fermentation broths.
2.Precision rotor assembly: Laser fully welded high-precision disc stacks with hydrodynamically optimised disc gaps establish stable laminar flow under high-speed rotation, enabling rapid separation of inclusion bodies, cell debris and supernatant to enhance separation efficiency and operational stability.
3.Stabilised pure water supply: Equipped with pure water storage tanks to deliver consistent pressure cooling and lubrication for mechanical seals. The system maintains water supply for a certain duration during unexpected water cut-offs to prevent dry friction of mechanical seals, extend equipment service life and secure production safety.
4.Aseptic isolation: Integrated aseptic isolation tanks utilise overflow water from sludge discharge to isolate ambient air and prevent microbial ingress into the separation system, sustaining aseptic conditions suitable for high-standard sterile manufacturing of vaccines, insulin and related products.
5.Integrated SIP module and aseptic maintenance: Centrifuges incorporate SIP sterilisation systems to support comprehensive, verifiable CIP and SIP before and after production, maintaining internal sterility in compliance with GMP and enabling continuous aseptic manufacturing.
6.Multi-point real-time temperature monitoring: Multiple temperature sensors track feed, separation and outlet temperatures continuously with closed-loop feedback to sustain materials within optimal temperature ranges, avoid damage to active components and improve product consistency and safety.
7.Real-time sampling capability: Supports aseptic sampling during production to monitor material status, clarity, biomass concentration and other key indicators, allowing timely tuning of process parameters for stable quality control.
8.Complete GMP validation documentation: Risk-based design philosophy implements validation and change control throughout design, manufacturing, commissioning and operation. The document package covers VP, CA, FMEA, DQ, IQ, OQ, PQ, VSR and full lifecycle validation files, ensuring controllable processes, authentic, complete and traceable data, and accelerating market access for international registration.
Automation Control Features
1.Pharmaceutical-oriented sequential control with bottom-layer CM architecture supporting on-demand calling for project-specific control functions. Built-in simulation enables functional testing of sensors without physical hardware.
2.Intuitive, reasonably partitioned human-machine interface for convenient operation.
3.Compact independent control logic with isolated program segments.
4.Program developed in accordance with ISA-88 pharmaceutical standards, offering flexible architecture for maintenance and expansion to shorten programming cycles.
5.High system safety with cyclic scanning for fast response and precise interlock protection.
6.Supports communication connection with MES systems to adapt to digital factories and intelligent workshops.
Alfa Laval
1.Product features: Alfa Laval disc stack centrifuges are recognised for high efficiency, low shear and fully enclosed construction. The CF-series high-speed disc stack centrifuges adopt patented bottom-feed design to deliver gentle acceleration with limited shear, maximising cell integrity while operating at high separation factors to remove minor debris from cellular autolysis. Units are equipped with CIP and SIP systems for deadleg-free cleaning and support aseptic operation.
2.Application scope: Widely deployed in biopharmaceuticals, food processing, chemical and petrochemical industries. Within antibody manufacturing, they are primarily used for cell culture broth clarification to remove cells and debris and supply high-quality feedstock for downstream purification.
Siemens
1.Product features: Siemens disc stack centrifuges prioritise automation and intelligent control. Integrated advanced control systems enable automatic feeding, sludge discharge, cleaning, startup and shutdown to improve operational convenience and productivity. Energy-efficient motors and transmission systems reduce power consumption and operational costs.
2.Application scope: Applied extensively in biopharmaceuticals, chemical and environmental industries. For antibody manufacturing, Siemens centrifuges are suitable for cell culture broth clarification, fermentation broth separation and product concentration, supporting continuous large-scale production via automated control.
GEA Group
1.Product features: GEA disc stack centrifuges deliver high separation efficiency and robust reliability. Advanced disc design and manufacturing technologies expand available separation area and separation factor for efficient solid-liquid and liquid-liquid separation. Optimised mechanical construction ensures stability and durability for prolonged continuous operation under demanding working conditions.
2.Application scope: Deployed in food, beverage, pharmaceutical, chemical and petrochemical sectors. In antibody purification, GEA centrifuges are used for broth clarification, product concentration and polishing, with high separation efficiency supporting productivity and product quality improvement.
Hitachi
1.Product features: Hitachi disc stack centrifuges feature high precision and operational stability achieved via precision machining and premium materials. User-friendly human-machine interfaces simplify operation and maintenance, while flexible architecture enables seamless connection with complementary equipment and systems.
2.Application scope: Applied in biomedicine, pharmaceutical, chemical and food industries. For antibody manufacturing, Hitachi centrifuges undertake broth clarification, purification and concentration, delivering consistent product quality via high-precision stable performance.
5.2 Trends of Technical Innovation
Main innovation directions for disc stack centrifuges are summarised as follows:
1.High-efficiency separation technology: Rising quality and efficiency requirements across biopharmaceutical and chemical sectors drive R&D of advanced separation technologies. Future disc stack centrifuges will adopt optimised disc geometry and manufacturing processes to expand separation area and separation factors for enhanced solid-liquid separation. Optimisation of disc shape and spacing extends material residence time between discs and improves separation outcomes. Research on novel separation materials and coatings will reduce material adsorption and product loss to boost recovery rates.
2.Intelligent monitoring and control: Intelligence constitutes a core development trend. Next-generation centrifuges will integrate diversified sensors and advanced control systems to continuously monitor feed flow, centrifugal force field, temperature and other parameters. Operating parameters including rotational speed, feed flow and sludge discharge cycles can be adjusted automatically according to pre-set protocols to achieve optimal separation performance and productivity. Intelligent control platforms will also support automatic fault diagnosis and early warning to improve equipment reliability and service life.
3.Energy conservation and environmental protection: Against the backdrop of energy constraints and stricter environmental regulations, energy-efficient design becomes a key focus. High-efficiency motors, transmission systems, variable frequency drives and energy recovery devices will be adopted to lower energy consumption. Enhanced sealing and cleaning performance minimise leakage and contamination risks to align with GMP specifications. Research on recyclable and biodegradable separation materials will reduce environmental impact.
4.Miniaturisation: Miniaturised and portable centrifuges will meet demands for laboratory research and on-site rapid testing. Compact centrifuges feature small footprint, lightweight construction and easy operation. Micro disc stack centrifuges suitable for small-volume rapid separation will provide convenient laboratory tools for researchers. Portable variants support on-site sample processing for environmental monitoring and food safety inspection.
5.Technology integration: Disc stack centrifuges will be increasingly integrated with complementary separation and analytical technologies to deliver integrated separation and purification solutions. Combinations with membrane separation technologies realise primary pre-clarification via disc stack centrifuges followed by fine polishing via membranes to improve separation efficiency and product quality. Integration with chromatographic analysis enables online monitoring of material composition and purity to support real-time process tuning. Integration with bioreactors and fermenters achieves automated continuous biopharmaceutical manufacturing to lift overall productivity.
6 Case Study: Industrial Adoption by Domestic Monoclonal Antibody Manufacturers
6.1 Typical Enterprise Application Cases
Disc stack centrifuges have been widely implemented in antibody purification workflows by domestic monoclonal antibody manufacturers:
1.Chia Tai Tianqing: As a leading domestic biopharmaceutical enterprise, Chia Tai Tianqing deploys Alfa Laval CF-series high-speed disc stack centrifuges for monoclonal antibody manufacturing. The centrifuges undertake cell culture broth clarification to remove cells and debris and provide high-quality supernatant for downstream affinity chromatography. Deployment of disc stack centrifuges improves antibody recovery by 15%, achieves purity above 98%, and reduces production costs by 20% for a cancer-targeting monoclonal antibody product.
2.Shijiazhuang Ouyi Pharmaceutical: Shijiazhuang Ouyi Pharmaceutical introduces disc stack centrifuge technology for monoclonal antibody production. After clarification, cell debris removal efficiency exceeds 95%, significantly lowering loading on depth filters and extending filter service life. Gentle separation conditions confine antibody activity loss within 3%, securing therapeutic efficacy. The high throughput of disc stack centrifuges satisfies capacity expansion requirements for large-scale manufacturing.
3.Henlius: Henlius, an international innovative biopharmaceutical firm, adopts advanced disc stack centrifuges for monoclonal antibody production. Effective clarification reduces impurity interference and improves efficiency of affinity and ion exchange chromatography. Low particulate levels in clarified supernatant benefit viral filtration and guarantee antibody safety. Production data shows that disc stack centrifuges increase viral filtration flux by 25% with viral removal efficiency above 99.95%, supporting high-quality antibody manufacturing.
6.2 Application Outcomes and Industrial Feedback
Domestic monoclonal antibody manufacturers report positive operational feedback on disc stack centrifuges:
1.Improved purification efficiency: Efficient broth clarification delivers cleaner supernatant for downstream processing and lifts overall purification productivity. Industrial feedback indicates antibody recovery rises by 10%–20%, purification cycle time shortens by 20%–30%, and manufacturing throughput increases substantially.
2.Sustained antibody activity: Fully enclosed architecture and gentle separation minimise protein denaturation. Industrial data confirms antibody activity loss can be controlled within 5%, outperforming conventional separation technologies and securing therapeutic efficacy.
3.Lower production costs: Enhanced clarification reduces depth filter capsule consumption by 50%–70%, cutting operational expenditure and mitigating production interruptions caused by filter fouling. Manufacturers report overall production cost reductions of 20%–30% with significant economic benefits.
4.Elevated product quality: Seamless integration with downstream purification steps builds high-efficiency workflows to improve antibody quality. Manufacturers achieve antibody purity above 98% with HCP residuals below 1 ppm, complying with U.S. FDA standards.
5.Stable equipment performance: Premium brands including Alfa Laval and Siemens deliver stable, low-failure operation with manageable maintenance costs. Integrated CIP and SIP systems enable deadleg-free automated cleaning, reduce manual labour and shorten cleaning cycles.
6.Professional technical support: Suppliers provide timely technical troubleshooting, process guidance and operator training, minimising production downtime and supporting enterprises to optimise operating procedures and process parameters.
7 Conclusion
Disc stack centrifuges occupy an irreplaceable position in antibody purification workflows. Their powerful separation capacity, capability to preserve protein activity and cost-saving advantages render them essential equipment for monoclonal antibody manufacturers. Driven by continuous technical advancement, disc stack centrifuges will deliver stronger support for biopharmaceutical development, enabling enterprises to achieve high-efficiency, low-cost antibody manufacturing and satisfy global market demand for high-quality antibody therapeutics.
